Small Biotech Companies Look to Benefit From Shift to "First to File" Patent System

NEW YORK, NY--(Marketwire -05/03/12)- Biotech stocks have continued to provide investors with strong gains in 2012. The iShares NASDAQ Biotechnology Index (IBB) is up nearly 20 percent year-to-date. The passage of the America Invents Act will look to benefit the Biotechnology Industry going forward "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system," BIO President and CEO Jim Greenwood stated in a press release. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Biosante Pharmaceuticals Inc. (BPAX - News) and Advanced Cell Technology, Inc. (ACTC.OB - News).

Access to full reports can be found at:

"Small biotechnology companies rely heavily on their patents to attract investment," and "they will benefit from the improvements to our nation's patent system made by this legislation," added Greenwood. The America Invents Act (AIA) will shift the patent system from a "first to invent" to a "first to file" system, the first major change to the patent system in over 60 years. Under the "first to invent" system the first inventor to file for a patent will be awarded priority, regardless if the inventor was the first to invent it. Most major countries are already following the "first to file" patent system.

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

BioSante is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA). In March the company reported that its net loss was $51.6 million or $0.52 per share for the year ended December 31, 2011, compared to a net loss of $46.2 million or $0.70 per share for 2010.

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. The company recently announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company's three ongoing clinical trials, have recently authorized the Company to move forward with enrollment and treatment of additional patients with Stargardt's disease (SMD).

Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: